Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Hepatitis C Opportunities Light Up Infectious Disease Partnering Landscape

Executive Summary

"Without question, hepatitis C is the number one exciting area in infectious diseases," insists Paul Zhang, a principal in the health care advisory group Easton Associates, LLC.

You may also be interested in...



Achillion Aiming For Best-In-Class Protease Inhibitor, Working On Home-Grown Hep C Cocktail

While hepatitis C drug developers ponder the safety and tolerability issues likely to arise when direct-acting antivirals are combined in cocktails against the virus, Achillion Pharmaceuticals, Inc., a small company in New Haven, CT, is working on a portfolio of candidates it says not only combine safely, they work better in combination.

Achillion Aiming For Best-In-Class Protease Inhibitor, Working On Home-Grown Hep C Cocktail

While hepatitis C drug developers ponder the safety and tolerability issues likely to arise when direct-acting antivirals are combined in cocktails against the virus, Achillion Pharmaceuticals, Inc., a small company in New Haven, CT, is working on a portfolio of candidates it says not only combine safely, they work better in combination.

Infectious Diseases Space Wide Open For Partnering Beyond Hep C, Conference Finds

The recent spotlight on hepatitis C doesn't mean that's the only hot area in infectious diseases for deals.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS052722

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel